Keywords
Chronic disease
Young people
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the characteristics of Multiple Sclerosis (MS). Bibliographic Review: MS is a potentially progressive autoimmune neurological disorder of the central nervous system resulting from an autoimmune attack on the white matter. It is one of the main causes of neurological symptoms in young adults, with no known cure, predominantly affecting patients aged between 20 and 40 years. The most common manifestations are optic neuritis and brainstem and spinal cord syndrome. Final considerations: Multiple Sclerosis is a demyelinating disease of the central nervous system that typically affects young people and has a long-term chronic course. Although there is no cure for MS, early symptom control and disease progression are associated with delayed disability and better long-term outcomes. Disease-modifying therapies are the pharmacological basis of MS therapy. In addition, a multidisciplinary treatment that includes a physical therapist, speech therapist, occupational therapist and psychologist should be carried out in order to improve the patient's quality of life and autonomy, in addition to minimizing the psychological effects of the disease.
References
BAIRD JF, et al. Therapies for mobility disability in persons with multiple sclerosis. Expert Rev Neurother, 2018; 18(6): 493-502.
BILBAO MM, et al. Multiple sclerosis: Pregnancy and women's health issues. Neurologia (Engl Ed), 2019; 34(4): 259-269.
BOWEN J, et al. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy. Adv Ther, 2020; 37(7): 3163-3177.
COTSAPAS C, et al. Multiple sclerosis. Handb Clin Neurol, 2018;148: 723-730.
GOLDSCHIMIDT C, MCGINLEY MP. Advances in the Treatment of Multiple Sclerosis. Neurol Clin, 2021; 39(1): 21-33.
GUERRERO BL, SICOTTE NL. Microglia in Multiple Sclerosis: Friend or Foe? Front Immunol, 2020; 11: 374.
HAUSER SL, CREE BAC. Treatment of Multiple Sclerosis: A Review. Am J Med, 2020;133(12): 1380-1390.
HORTON DB, REDER AT. Medications for Multiple Sclerosis and Risk of Malignancy: What Next? Neurotherapeutics, 2021; 18(3): 1650-1653.
JACQUIN-COURTOIS S, et al. Multiple sclerosis: A special issue in the Annals of Physical and Rehabilitation Medicine. Ann Phys Rehabil Med, 2020; 63(2): 91-92.
KAUSAR SA. Multiple sclerosis. Clin Med (Lond), 2020; 20(5): e138-e139.
KLINEOVA S, LUBLIN FD. Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med, 2018; 8(9): a028928.
LANGER-GOULD A, et al. The Multiple Sclerosis Treatment Optimization Program. Ann Clin Transl Neurol, 2021; 8(11): 2146-2154.
LECHNER-SCOTT J, et al. Is multiple sclerosis a risk factor for infections? Mult Scler Relat Disord, 2020; 41: 102184.
LEMUS HN, et al. Multiple Sclerosis: Mechanisms of Disease and Strategies for Myelin and Axonal Repair. Neurol Clin, 2018; 36(1): 1-11.
MORTAZAVI M, et al. Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies. Neuroimage Clin, 2021; 31: 102734.
RICCIO P, ROSSANO R. Diet, Gut Microbiota, and Vitamins D + A in Multiple Sclerosis. Neurotherapeutics, 2018; 15(1): 75-91.
RISPOLI MG, et al. Contribution of Metabolomics to Multiple Sclerosis Diagnosis, Prognosis and Treatment. Int J Mol Sci, 2021; 22(20): 11112.
RUIZ F, et al. Resolution of inflammation during multiple sclerosis. Semin Immunopathol, 2019; 41(6): 711-726.
SORENSEN PS, et al. The Multiple Sclerosis Care Unit. Mult Scler, 2019; 25(5): 627-636.
TARLINTON RE, et al. Role of Viruses in the Pathogenesis of Multiple Sclerosis. Viruses, 2020; 12(6): 643.
TOMASOVIC S, et al. Epidemiology of Pharmacological Treatment of Multiple Sclerosis in Croatia. Psychiatr Danub, 2021; 33(13): 204-208.
WANG H. MicroRNAs, Multiple Sclerosis, and Depression. Int J Mol Sci, 2021; 22(15): 7802.
WIENDL H, et al. Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper). Nervenarzt, 2021; 92(8): 773-801.
YAHYA AS, KHAWAJA S. Electroconvulsive Therapy in Multiple Sclerosis: A Review of Current Evidence. Prim Care Companion CNS Disord, 2021; 23(2): 20r02717.
YAMOUT BI, ALROUGHANI R. Multiple Sclerosis. Semin Neurol, 2018; 38(2): 212-225.